Article Versions Notes

Senguttuvan RN, Cho H, Wu X, Frankel PH, Ruel N, Yost SE, Kebria M, Han E, Song M, de Leon M, et al. The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate. Antioxidants. 2025; 14(3):345. https://doi.org/10.3390/antiox14030345

Senguttuvan, Rosemary N., Hyejin Cho, Xiwei Wu, Paul H. Frankel, Nora Ruel, Susan E. Yost, Mehdi Kebria, Ernest Han, Mihae Song, Maria de Leon, and et al. 2025. "The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate" Antioxidants 14, no. 3: 345. https://doi.org/10.3390/antiox14030345

Senguttuvan, R. N., Cho, H., Wu, X., Frankel, P. H., Ruel, N., Yost, S. E., Kebria, M., Han, E., Song, M., de Leon, M., Invernizzi, M., Eng, M., Tinsley, R., Salehian, B., Li, A., Schmolze, D., Chang, S., Arias-Stella, J., & Dellinger, T. H. (2025). The Anti-Cancer Role of Pterostilbene in Endometrial Cancer: A Phase II Prospective, Randomized, Window-of-Opportunity Clinical Trial with Megestrol Acetate. Antioxidants, 14(3), 345. https://doi.org/10.3390/antiox14030345